- ►milray.org [PDF] - Free from Publisher WT Cefalu - Diabetes Care, 2004 - Am Diabetes Assoc OBJECTIVE—To comprehensively review the progress to date on the development of
alternative routes for insulin delivery. ... RESEARCH DESIGN AND
METHODS—Study data were collected through a Medline review. Cited by 71 - Related articles - BL Direct - All 10 versions
DR Owens - Nature Reviews Drug Discovery, 2002 - medicina.iztacala.unam.mx The identification of the pancreas as the site of the defect that causes
diabetes mellitus by von Mehring and Minkowski in 1889 led eventually to the
extraction of insulin by Banting and Best in 1921 (REF. 1). Shortly after, ... Cited by 62 - Related articles - BL Direct - All 5 versions
DR Owens, B Zinman, G Bolli - Diabetic Medicine, 2003 - interscience.wiley.com Attempts at replicating physiological insulin secretion, as a means of restoring
the normal metabolic milieu and thereby minimizing the risk of diabetic
complications, has become an essential feature of insulin treatment. ... Cited by 134 - Related articles - BL Direct - All 5 versions
JA Stoever, JP Palmer - Diabetes Technology & Therapeutics, 2002 - liebertonline.com The recent development of inhaled insulin for the treatment of diabetes has the
potential to significantly improve patient compliance and diabetes control.
Preliminary studies have shown inhaled insulin to be effective in lowering ... Cited by 25 - Related articles - BL Direct - All 4 versions
RP Radermecker, JL Sélam - Rev Med Liège, 2005 - rmlg.ulg.ac.be L'insulinothérapie a débuté le 11 janvier 1922 avec la première
administration d'insuline à un patient diabétique, dénommé Léonard Thomp-
son, par Banting et Best, ouvrant la voie à la for- midable aventure de l' ... Cited by 2 - Related articles - View as HTML - All 3 versions
- ►diabetesjournals.org RR Henry, SRD Mudaliar, WC Howland III, N … - Diabetes Care, 2003 - Am Diabetes Assoc RESULTS—Inhaled insulin showed area under the curve (AUC) (0–360 min) values
that were significantly greater for healthy subjects than for asthmatic subjects
(P = 0.013), whereas no difference was observed for maximum concentration ... Cited by 98 - Related articles - BL Direct - All 5 versions
- ►diabetesjournals.org KM Rave, L Nosek, A de la Peña, M Seger, … - Diabetes Care, 2005 - Am Diabetes Assoc RESULTS—HIIP demonstrated a similar rapid onset but an extended time exposure
and a prolonged duration of effect (late t 50% 412 vs. 236 min, P < 0.001)
compared with SC lispro. The HIIP versus SC lispro doses of 2.6 mg vs. 6 ... Cited by 61 - Related articles - BL Direct - All 5 versions
S Clement, P Dandona, JG Still, G Kosutic - Metabolism, 2004 - Elsevier An effective, orally administered insulin product would be of substantial
benefit in the treatment of patients with diabetes mellitus. This phase I/II
clinical trial was the first to investigate the safety and effectiveness of ... Cited by 43 - Related articles - All 10 versions
- Free from Publisher AD Perera, C Kapitza, L Nosek, RS Fishman, … - Diabetes Care, 2002 - Am Diabetes Assoc RESULTS—INH showed a bioavailability (0–8 h postdosing) of 16% and
biopotency of 13% relative to SC. Comparison of the CVs (%) for area under the
curve for serum insulin and GIR between INH and SC showed no significant ... Cited by 48 - Related articles - BL Direct - All 5 versions
- Free from Publisher A Himmelmann, J Jendle, A Mellén, AH … - Diabetes Care, 2003 - Am Diabetes Assoc RESULTS—Pharmacokinetic results for evaluable subjects were derived from serum
insulin profiles. The amount of insulin absorbed during the first 6 h after
dosing (area under the exogenous serum insulin curve from 0 to 6 h [AUC ... Cited by 100 - Related articles - BL Direct - All 5 versions
